跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
INCRESYNC 25/45 mg Tablet - SFDA Drug Approval Details
Approvals
/
SFDA
/
INCRESYNC 25/45 mg Tablet
Authorized
NCE
INCRESYNC 25/45 mg Tablet
Unknown
🇸🇦 Saudi Food and Drug Authority
Approval Date
N/A
Approval ID
2722ba0020341af3
Company
Unknown
Type
NCE
Approval Details
Approval Id
2722ba0020341af3
Drug Approval Sfda Name
INCRESYNC 25/45 mg Tablet
Trade Name
INCRESYNC 25/45 mg Tablet
Generic Name
ALOGLIPTIN,PIOGLITAZONE
Register Number
321-334-19
Register Year
2019
Drug Type
NCE
Route Of Administration
Oral use
Package Type
Blister
Package Size
28
Legal Status
Prescription
Authorization Status
Valid
Marketing Status
Marketed
Product Control
Uncontrolled
Storage Conditions
store below 30°c
Shelf Life
36 Months
Distribution Site
Pharmacy
Description Code
14000001054-70-100000073664
Price
175.75
Active Ingredients
Authorized
Quick Info
Agency
SFDA
Country
🇸🇦
Approval ID
2722ba0020341af3
Type
NCE
Back to SFDA Approvals